10.30.24 – CDC Updates Recommendations for COVID-19 and Pneumococcal Vaccinations
CDC Recommends Second Dose of 2024-2025 COVID-19 Vaccine for 2 Groups:
– 65 Years and Older and for People Who are Moderately or Severely Immunocompromised
– Everyone 6 months and older who are moderately or severely immunocompromised
CDC also lowered the age for which it recommends adult pneumococcal vaccination from 65 to 50 years old. Pneumococcal bacteria can cause serious illnesses, including pneumonia, meningitis, and bloodstream infections.
10.25.24 – FDA Approves First Ever RSV Vaccine Indicated for Adults Younger than 50: Abrysvo by Pfizer
The FDA has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo for adults ages 18 to 59 who are at an increased risk of developing lower respiratory tract disease (LRTD). The approval makes the shot the first of its kind for adults who are younger than 50 years old. Among U.S. adults ages 18 to 49, 9.5% have an underlying chronic condition that increases their risk of developing severe disease, Pfizer said. In the 50 to 64 age group, the prevalence of at-risk individuals rises to 24%.
Abrysvo is a vaccine indicated for:
– the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in people 60 years of age and older
– the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV
– pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.
10.8.24 – The CDC recommends an RSV vaccine for all adults ages 75 years and older and for adults ages 60–74 years who are at increased risk of severe RSV.
Three RSV vaccines are licensed by the U.S. Food and Drug Administration for use in adults ages 60 and older in the United States:
– GSK’s Arexvy
– Moderna’s mResvia
– Pfizer’s Abrysvo
If your patient has already gotten an RSV vaccine, you do not need to get another one at this time. Your patients can get one at any time, but the best time to get vaccinated is in late summer into fall.
9.18.24 – GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK announces administration of its respiratory syncytial virus (RSV) vaccine: Arexvy and Shingles shot: Shingrix – together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
The trial testing the immune response of co-administration of GSK’s blockbuster vaccines, Shingrix and Arexvy, in adults over 50 years of age, met the main goal of the study.
RSV causes over 177,000 hospitalizations and 14,000 deaths in the United States annually, while over 1 million people develop shingles every year in the country.
8.24.24 – COVID continues to mutate and spread through our communities, with winter approaching, now is the time to protect your patients with the FDA approved updated COVID formulation.
he FDA has authorized the use of new vaccines from Pfizer/BioNTech and Moderna which have been designed to defend against the Omicron KP.2 variant of SARS-CoV-2.
– A new omicron variant, KP.3.1.1, is beginning to eclipse KP.2 as the dominant strain of the virus in the United States.
– The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1. The FDA endorsed both the Pfizer and Moderna adapted vaccines for people ages 6 months and older.
– The KP.2 adaptation is based on FDA guidance, which stated that KP.2 is the preferred strain for COVID-19 vaccines for the US 2024-2025 fall and winter season, if feasible
“Vaccination continues to be the cornerstone of COVID-19 prevention,” Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research (CBER), said in a release. “Given waning immunity of the population from previous exposure to the virus and from prior vaccination, we strongly encourage those who are eligible to consider receiving an updated COVID-19 vaccine to provide better protection against currently circulating variants.”
7.31.24 – Groundbreaking: Bavarian Nordic begins commercial launch of mpox vaccine Jynneos in US
After years relying on the U.S. government to stockpile and distribute Jynneos, Bavarian Nordic is launching the mpox vaccine into the commercial market.
Jynneos, the only FDA-approved mpox vaccine, is now commercially available in the U.S., Bavarian Nordic announced Tuesday. The commercial rollout means that interested individuals can access the shot at local pharmacies and physician offices, in addition to the limited number of clinics designated by health authorities.
The launch builds on Jynneos’ availability through public health channels since an mpox—then known as monkeypox—outbreak in 2022. It also follows a unanimous decision in October from the U.S. CDC’s Advisory Committee on Immunization Practices to recommend Jynneos as a routine vaccination in adults at risk of mpox infection, backing the shot’s use beyond an outbreak.
7.15.24 – CDC Recommends Vaxelis in American Indian and Alaska Native Populations
Invasive Haemophilus influenzae type b (Hib) disease is a rare but serious bacterial infection that disproportionally affects American Indian and Alaska Native infants. Until now, PedvaxHIB was the only Hib vaccine preferentially recommended over other Hib vaccine options for these infants because it provides a protective antibody response after the first dose.
ACIP voted to recommend that Vaxelis be included in the preferential recommendation for American Indian and Alaska Native infants based on the Hib component. New immunogenicity data after the first dose of Vaxelis are available now and supported the recommendation.
6.21.24 – Merck’s First Ever Adult Pneumococcal Vaccine Receives FDA Nod
The FDA has approved the world’s first pneumococcal disease vaccine designed for adults, signing off on Merck’s Capvaxive (formerly V116) and positioning it to become the primary shot used by seniors to protect against the bacterial infection.
There are more than 150,000 adults each year in the United States who are hospitalized with pneumococcal disease. With serious complications including bacteremia and pneumococcal meningitis, the case death rate for those hospitalized is 14%.
This groundbreaking new adult pneumococcal vaccine will protect patients and this disease.
5.13.24 – Sanofi and Novavax Announce Co-Exclusive Licensing Agreement to Co-Commercialize COVID-19 Vaccine and Develop Novel Flu-COVID-19 Combination Vaccines
- Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards
- Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering patients enhanced convenience and protection
4.29.24 – Access Vaccines Merck Discount Program Provides Lowest National Price on Gardasil
Access Vaccines Merck Discount Program Provides Lowest National Price on Gardasil
The Access Vaccines Merck Discount Program provides members with the lowest national price on Gardasil. GARDASIL 9 is a vaccine for patients 9 through 45 years of age for the prevention of certain cancers and other diseases caused by 9 types of human papillomavirus (HPV).
According to a CDC model in 2012-2016: In men, oropharyngeal cancer has been the most prevalent HPV-attributable cancer in the US. Certain HPV-related oropharyngeal cancers affect men (~10,500) ~5x more than women (~2,100).
The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Access Vaccines is proud to offer our members the lowest national price on Gardasil. Become a member today and save.
4.15.24 – Access Vaccines Now Offers Discount on GSK and Moderna Vaccines to Independent Pharmacies
Access Vaccines is proud to announce we are now able to provide discounted member pricing to Independent Pharmacies. For the first time in the history of PBG’s, Access Vaccines is now able to offer our services to Independent Pharmacies throughout the nation.
– Member discounts on GSK vaccines including Shingrix and Flu.
– Member discounts on all Moderna vaccines.
Independent Pharmacies can now take advantage of discount member pricing through Access Vaccines. Enroll your location or group in the Access Vaccines Pharmacy Discount Program today to save on your GSK and Moderna vaccine purchases.
4.10.24 – 2024-25 Influenza Vaccines Transitioning to Trivalent Formulation
U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) provided recommendations for the TIV viral strain selection of influenza vaccines, which align with the February 2024 World Health Organization (WHO) annual recommendations.
3.7.24 – Access Vaccines is Proud to Announce our Newest Partnership: Merck Vaccines
Proud to announce our newest partnership with Merck Vaccines. This partnership continues to expand our portfolio, bringing more options and savings to our members on all administered brands.
The Acces Vaccines Merck Discount Program offers qualifying members discounts on Merck Vaccines. The program provides the Lowest National Price on Gardasil, Rotateq and Vaxneuvance (PCV15). Access Vaccines members who join the Merck Discount program will receive discounts on all Merck Vaccines.
Contact Access Vaccines to join the Merck Discount Program and start saving on all your Merck Vaccine purchases today. Merck Discount Program.
2.2.24 – First Ever Covid-19 and Flu Test: Lucira by Pfizer
Groundbreaking lab technology provides fast results for patients during their visit. One test, two results. Access Vaccines members will now have the opportunity to purchase this new, groundbreaking test by Pfizer at discounted member rates. Lucira by Pfizer is the first and only test for both Covid-19 and Flu A + B. Combined testing device for fast, accurate, point-of-care testing powered by molecular technology. Test results in 30 minutes or less.
- First and only for Covid-19 and Flu A + B
- Discounts Available for AV Members
- Test costs are Reimbursable
- Convenient 3-in-1 testing
1.24.24 – Sanofi’s Groundbreaking Infant RSV Vaccine: Beyfortus is Now Back in Stock and Available at Discount Member Pricing for Access Vaccines Members
Supply issues eased: CDC resumes routine recommendations for Nirsevimab (Beyfortus) to protect infants and high-risk toddlers from severe RSV. On January 5, 2024 CDC issued a Clinician Outreach and Communicaiton Activity (COCA) emergency alert: Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season. CDC now recommends resuming adherence to the published ACIP recommendations for use of nirsevimab and provides considerations for individual facilities with limited supplies. Immunize.org is updating its standing orders template to reflect this change.
1.2.24 – Acccess Vaccines Merck Discount Program Provides Access Vaccines Members the Lowest National Price on Gardasil
Access Vaccines offers the lowest national price on Gardasil through the Merck Discount Program. The exclusive program provides members will discounts on Gardasil, Rotateq and all other Merck Vaccines.
- Lowest National Price on Gardasil
- Lowest National Price on Rotateq
- Discounts on all Merck Vaccines
11.14.23 – Pfizer’s 12+ yrs Covid Vaccine Now Available at Lowest National Price for Access Vaccines Members in “Never Frozen” Glass Prefilled Syringes
The FDA issued an update to the dosage and administration section of the COMIRNATY (COVID-19 Vaccine, mRNA) USPI to include COMIRNATY Single Dose Glass Prefilled Syringes. In addition to the previously included plastic prefilled syringe and Single Dose Vial presentations for individual 12 years of age and older, the USPI now includes (NDC 0069-2377-10, carton of 10 single dose prefilled syringes; NDC 0069-2377-01, single dose prefilled syringe). The glass prefilled syringes have never been frozen and will be available mid-November through wholesalers.
These glass prefilled syringes were developed to be stored in a refrigerator and are “NEVER FROZEN”, have never been frozen, and must be stored at 2°C to 8°C (35°F to 46°F) until the expiration date printed on the carton and syringe labels. DO NOT FREEZE.
- Product expiration is 6 months from when it was manufactured.
- The expiration of the product will be on the box and customers will use this date versus the need to relabel with prior product
- DO NOT FREEZE will be listed on the carton and highlighted in Pink
10.19.23 – CDC Recommends Pfizer or Sanofi RSV Vaccine to Provide Protection Against Infant RSV
ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32–36 weeks’ gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.
8.31.23 – GSK’s RSV Arexvy: RSV Vaccines Remains Effective Against Distinct Viral Variants
GSK’s Arexvy vaccine for respiratory syncytial virus (RSV) — the first to be approved for older adults — can remain effective against a range of variants and produces strong antibody responses against distinct viral strains, according to a new study. The study results, published in the journal Science Translational Medicine, indicate that the vaccine could offer enduring protection against both contemporary RSV and future variants, especially when combined with vaccine adjuvants.